Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...

Novartis (NVS) announced results from an updated analysis of the pivotal Phase 3 NATALEE trial of Kisqali that it says “underscore the extended ...

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

Siemens Healthineers announced today that it completed the acquisition of Advanced Accelerator Applications Molecular Imaging ...

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...

MSN Pharma was given FDA approval for its Entresto (sacubitril and valsartan) generic on 24th July, prompting a legal ...

Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset ...

Novartis Bangladesh Limited (“NBL”) announced on Thursday that the agreement by Novartis AG to transfer its shares in NBL to ...

The U.S. Court of Appeals has reportedly ruled against Novartis (NVS) in its bid to prevent the U.S. launch of a generic ...